Obinutuzumab Shows Efficacy in Systemic Lupus and Primary Membranous Nephropathy Trials
Obinutuzumab demonstrated superior efficacy in two separate phase 3 trials for systemic lupus erythematosus and primary membranous nephropathy, with statistically significant improvements in remission rates and disease response measures.